Keerthi Anpalagan
PhD Candidate and Research Assistant
B.Biomed (Hons)
keerthi.anpalagan@thekids.org.au
+61 499 100 655
https://www.linkedin.com/in/keerthi-anpalagan-235a543bKeerthi is an inquisitive, diligent, and motivated young scientist in the field of paediatric infectious disease. She has a Bachelor of Biomedical Science with first-class honours.
Keerthi has been dedicated to conducting research that improves the health and wellbeing of diverse patient groups since 2021. At present, she is a collaborative team member, within a multidisciplinary clinical trials team called SNAP, aiming to conduct research to the highest quality in children with Staphylococcus aureus bloodstream infections.
Keerthi's PhD focuses on examining the economic burden, optimising antibiotic treatment and diagnostic strategies for children with S.aureus bloodstream infections.
Education and Qualifications
- Doctor of Philosophy - University of Western Australia (2022- present)
- Bachelor of Biomedical Science (Honours) - University of Notre Dame, Perth (2018-2021)
Awards/Honours
- Australian Government Research Training Program Domestic Fees Offset Scholarship - University of Western Australia (2022-2025)
- University Postgraduate Award - University of Western Australia (2022-2025)
- Dean's Letter of Commendation (2020) - University of Notre Dame
Projects
SNAP-PY
There are an estimated 5000 episodes per year of bloodstream infections due to Staphylococcus aureus (golden staph) in Australia and an associated mortality of 20%. Despite this, there is little clinical trials evidence to guide best management.
October 2023
Published research
Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials
There is a recognized unmet need for clinical trials to provide evidence-informed care for infants, children and adolescents. This Special Communication outlines the capacity of 3 distinct trial design strategies, sequential, parallel, and a unified adult-pediatric bayesian adaptive design, to incorporate children into clinical trials and transform this current state of evidence inequity. A unified adult-pediatric whole-of-life clinical trial is demonstrated through the Staphylococcus aureus Network Adaptive Platform (SNAP) trial.
Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trial
The use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many guidelines, but there is limited evidence underpinning this.